Introgen, Colgate-Palmolive to co-develop anti-cancer oral health products

By Angela McDaniels

Seattle, Nov. 4 - Introgen Therapeutics Inc. said it has formed an alliance with Colgate-Palmolive Co. to develop topical products that use Introgen's molecular therapies to target oral cancer and pre-cancerous conditions of the mouth.

Colgate-Palmolive purchased $20 million of Introgen shares on Friday and has priority rights regarding products that may be developed through the alliance.

Introgen said its academic collaborators are conducting a phase-½ clinical study for INGN 234 - a mouthwash formulation that delivers a tumor-suppressing agent - in patients diagnosed with leukoplakia, a pre-cancerous condition.

"The tissues lining the oral cavity may be particularly well suited and accessible targets for molecular therapies that can arrest abnormal cell growth without harming normal cells," said David G. Nance, chief executive officer of Introgen, in a company press release.

Excluded from the alliance with Colgate are Introgen's current portfolio of cancer product candidates including Advexin, INGN 241, INGN 225 and INGN 401.

Introgen is an Austin, Texas-based biopharmaceutical company focused on the development of targeted molecular therapies for the treatment of cancer and other diseases.

Colgate-Palmolive is a consumer products company headquartered in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.